OptimizeRx Corporation
NASDAQ:OPRXMedical - Healthcare Information Services
-$0.05 today
- Market cap
- $138.21M
- Beta
- 1.10
- P/E (TTM)
- 13.8
- EPS (TTM)
- $0.36
Volume 0.18M
Average 0.47M
OPRX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
OptimizeRx CorporationNASDAQ: OPRX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $1.06M fell 2.7% year over year, behind the -1.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.3% from the prior quarter. Over 3 fiscal years it compounded at +28.9% a year.
Context
- Depreciation & amortization amounted to 4.0% of revenue in FY2025, down 0.7 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -2.7% toward the trailing-twelve-month pace of -1.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 4.33M USD
- Year-over-year change
- -0.0%
- 4-year CAGR
- +21.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.33M | -0.0% |
| FY2024 | 2024-12-31 | 4.33M | +80.2% |
| FY2023 | 2023-12-31 | 2.4M | +18.8% |
| FY2022 | 2022-12-31 | 2.02M | +2.9% |
| FY2021 | 2021-12-31 | 1.97M | — |
Depreciation & Amortization vs competitors
How OPRX compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -1.4% is the 8th highest of 10, against a peer median of +13.0%.
- Depreciation & amortization amounts to 4.0% of revenue for OPRX, versus a peer median of 10.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $55.54M USD | +5.2% | -0.5% | 23.3% | |
| LTM Mar 2026 | $43.33M USD | +48.8% | -17.1% | 12.5% | |
| LTM Mar 2026 | $9.98M USD | +13.0% | +19.6% | 12.3% | |
| LTM Mar 2026 | $8.25M USD | +34.9% | +13.0% | 6.0% | |
| LTM Feb 2026 | $6.47M USD | -19.3% | +32.0% | 8.0% | |
| LTM Mar 2026 | $4.3M USD | -1.4% | +28.9% | 4.0% | |
| LTM Mar 2026 | $3.56M USD | -9.6% | -1.3% | 2.6% | |
| LTM Mar 2026 | $3.32M USD | +1.4% | -6.7% | 2.6% | |
| LTM Mar 2026 | $1.34M USD | +611.6% | +25.6% | 34.2% | |
| LTM Mar 2026 | CA$72.77K CAD | +119.6% | +133.5% | — | |
| Peer median (excluding OPRX) | — | +13.0% | +13.0% | 10.2% | |
Competitors are the stored peer set for OPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 378.08K | (11.44M) | (17.57M) | (20.11M) | 5.13M |
| Depreciation & Amortization | 1.97M | 2.02M | 2.4M | 4.33M | 4.33M |
| Deferred Income Tax | 0 | 0 | 0 | 1.45M | 1.21M |
| Stock-Based Compensation | 5.49M | 15.75M | 13.72M | 11.47M | 6.96M |
| Change in Working Capital | (7.19M) | 3.96M | (15.55M) | 921K | 816K |
| Accounts Receivables | (6.99M) | 2.28M | (8.71M) | (2.17M) | 460K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (603.09K) | 555.4K | 195K | (72K) | (520K) |
| Other Working Capital | 408.65K | 1.12M | (7.03M) | 3.16M | 876K |
| Other Non-Cash Items | 80K | 363.51K | 9.76M | 6.83M | 264K |
| Operating Cash Flow | 726.04K | 10.65M | (7.24M) | 4.89M | 18.72M |
| Capital Expenditures | (486K) | (244.57K) | (871K) | (112K) | (58K) |
| Acquisitions (Net) | 0 | (2M) | (80.41M) | 0 | 0 |
| Purchases of Investments | 0 | (55.93M) | (162.78M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 218.71M | 0 | 0 |
| Other Investing Activities | (385.68K) | (163.56K) | (774K) | (338K) | 126K |
| Investing Cash Flow | (486K) | (58.18M) | (25.34M) | (450K) | 68K |
| Debt Repayment | 0 | 0 | 36.02M | (4M) | (8M) |
| Common Stock Issued | 70.67M | 0 | 0 | 0 | 352K |
| Common Stock Repurchased | 0 | (20.02M) | (7.52M) | (911K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.25M | 1.07M | (278K) | 0 | (1.15M) |
| Financing Cash Flow | 73.92M | (18.95M) | 28.22M | (4.91M) | (8.8M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 74.16M | (66.47M) | (4.36M) | (472K) | 9.99M |
| Free Cash Flow | 240.04K | 10.41M | (8.11M) | 4.78M | 18.66M |
OptimizeRx Corporation
NASDAQ:OPRX
Intrinsic Alpha fair value
Locked
Current Price
$7.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.